Form 4: Metsera Director Sells Shares in Pfizer Merger

Metsera Director Jon P. Stonehouse disposed of common stock, restricted stock units, and stock options as part of the company's acquisition by Pfizer Inc. for $65.60 per share plus contingent value rights.

Summary

• Jon P. Stonehouse, a Director of Metsera, Inc., reported changes in his beneficial ownership due to the merger of Metsera with Mayfair Merger Sub, Inc., a wholly-owned subsidiary of Pfizer Inc.
• The merger became effective on November 13, 2025, with Metsera continuing as a wholly-owned subsidiary of Pfizer.
• Each outstanding share of Metsera common stock was converted into the right to receive $65.60 in cash per share and one contractual contingent value right (CVR).
• Outstanding stock options were cancelled in exchange for cash (Closing Amount minus exercise price, multiplied by shares) and one CVR per share. Unvested options' cash and CVRs are subject to original vesting, with full vesting on the first anniversary of the merger, conditional on continued service.
• Restricted Stock Units (RSUs) were cancelled and converted into cash (Closing Amount multiplied by shares) and CVRs, with these payments not subject to vesting.
• Stonehouse disposed of 2,688 shares of common stock, 2,688 restricted stock units, and 47,730 stock options as a result of the merger.

Sentiment

Score: 7

Explanation: The merger's completion provides a fixed cash payment and potential upside via CVRs for equity holders, with RSUs immediately unvested. While Metsera is no longer independent, the terms appear favorable.

Positives

• Shareholders received a fixed cash payment of $65.60 per share for their common stock.
• Shareholders and option/RSU holders also received contingent value rights (CVRs), offering potential additional payments based on future milestones.
• RSU holders received cash and CVRs that are not subject to further vesting, providing immediate liquidity and potential upside.
• Stock option holders received cash for the in-the-money portion of their options ($45.79 per option for Stonehouse's options) and CVRs.

Negatives

• Metsera, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Pfizer Inc.
• The reporting person no longer holds direct beneficial ownership in Metsera, Inc. common stock, options, or RSUs.
• Unvested stock options' cash and CVRs are subject to continued service with Pfizer or its subsidiaries for one year post-merger to fully vest.

Risks

• The value of the contingent value rights (CVRs) is uncertain and depends on the achievement of specified milestones, which may or may not occur.
• For unvested stock options, the cash payment and CVRs are subject to the holder's continued service with Pfizer or its subsidiaries through the first anniversary of the merger, posing a risk of forfeiture if service is terminated.

Future Outlook

The future outlook for former Metsera shareholders and equity award holders includes potential additional cash payments from contingent value rights (CVRs) upon the achievement of specified milestones. For unvested stock options, the associated cash and CVRs will vest fully on the first anniversary of the merger, provided the holder maintains continued service with Pfizer or its subsidiaries.

Industry Context

This filing reflects a common trend in the pharmaceutical and biotechnology sectors where larger established companies like Pfizer acquire smaller, innovative firms like Metsera to expand their pipeline, technology, or market presence. The use of contingent value rights (CVRs) is a frequent mechanism in such acquisitions, allowing the acquirer to mitigate risk while providing target company shareholders with upside potential tied to the acquired assets' future performance.

Comparison to Industry Standards

• The acquisition price of $65.60 per share, combined with CVRs, is a standard structure for biotech/pharma mergers, often reflecting a premium over pre-announcement trading prices and incorporating future value potential.
• The inclusion of CVRs is a common practice in the life sciences industry, seen in deals such as Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia, where payments are tied to regulatory approvals or sales milestones.
• The treatment of equity awards (options and RSUs) with a mix of cash and CVRs, and service-based vesting for unvested awards, aligns with typical industry practices designed to retain key personnel post-acquisition.

Stakeholder Impact

• Shareholders: Received $65.60 per share in cash and one CVR per share, providing immediate value and potential future upside.
• Equity Award Holders (Options/RSUs): Received cash and CVRs in exchange for their awards. RSU holders' awards became immediately unvested. Unvested option holders' cash and CVRs are subject to continued service for one year post-merger.
• Employees (specifically those with unvested options): Retention incentive through service-based vesting of merger consideration for unvested options.
• Metsera, Inc. as an entity: Ceased to be an independent public company, becoming a wholly-owned subsidiary of Pfizer Inc.

Next Steps

• Achievement of specified milestones for contingent value rights (CVRs) to trigger additional payments.
• Continued service of unvested stock option holders with Pfizer or its subsidiaries through the first anniversary of the merger for full vesting of associated cash and CVRs.

Key Dates

Keywords

Metsera, Pfizer, Merger, Acquisition, Form 4, Beneficial Ownership, Contingent Value Rights, CVR, Stock Options, Restricted Stock Units, RSU, Jon P. Stonehouse